Korea Research Institute of Bioscience and Biotechnology

Enzychem Lifesciences Corporation

Hyundai Electronics Industries Co. Ltd.

Lg Chem, Ltd

Hyundai Mobis Co., Ltd.

Jae Wha Kim

Kyung Seop Ahn

Ki-Young Sohn

Ho Bum Kang

Sei Ryang Oh

Ki Young Sohn

Hee Gu Lee

Sei-Ryang Oh

Doo Young Kim

Young Il Yeom

Eun Young Song

Yong-Hae Han

Tae Suk Lee

Jong Koo Kang

Jae Sung Song

Hyeong Kyu Lee

In S Chung

Jung Hee Kim

Myung-Hwan Kim

Sun Young Yoon

Myung Hwan Kim

Chang Hyun Yoo

Young Ho Kim

Ok-Kyoung Kwon

Young Sik Jung

Young-Jun Kim

Kyung-Sook Chung

Mi Sun Won

Soo Min Kim

Jin Won Lee

Min Han Kwak

Hyun Woo Oh

Tae-Suk Lee

Seung Ho Kim

JongKoo Kang

Kyung Chan Park

Jae C Om

Beom Su Park

Jin H Kim

Hye Kyung Kim

Hyuk Hwan Song

Dur Han Kwon

Joo Heon Kim

Myung-hwan Kim

Jae Min Shin

Jin Seon Jeong

Young Eun Ko

Jong Tae Kim

Min Ah Kang

Da Jung Ji

Saeho Chong

Han S Yoon

Seon-Young Kim

Jae Kyung Yang

Do Young Yoon

Ho Kyung Chun

Woo Jeong Oh

Sang Rock Lee

InPyo Choi

Yeong Ah Cheon

Yong-Kyung Choe

Mi-Young Park

Mi Young Cho

Hyeong-Kyu Lee

Ho-Bum Kang

Seung Chul Choi

Da Chung Ji

Jang Mi Sun

Hyang Sin Lee

Jae Jong Go

Piseth Khiev

Jin Soo Yook

Yi Hua Pei

Seon Young Kim

Jang Mi Son

Byeong Hwa Jeon

Khiev Piseth

Mi Young Park

Jae Mine Yoo

In Seong Choe

Kyoung Eun Baek

Jong Seok Lim

Jin Sook Kim

Jongkoo Kang

Disclosed are a glycerol derivative that is useful for improving, preventing or treating inflammation-related diseases by inhibiting overexpression of various inflammatory cytokines such as IL-4, IL-6 and so on, or chemokine CXCL8 and reducing migration of HL-60 cell lines, preparation method therefor, and an immunomodulator containing the same as active ingredient. It includes a glycerol derivative represented by Chemical formula 2 or 3 in the specification.

Glycerol derivative, preparation method therefor, and immunomodulator comprising same as effective ingredient

Disclosed are a novel 1,2-diacylglycerol compound that useful for improving, preventing or treating inflammation-related diseases by inhibiting overexpression of various inflammatory cytokines such as IL-4 and IL-6 or chemokine CXCL8 related to the migration of inflammatory cells, a method for preparing the same, and an immunomodulator containing the same as an active ingredient. The 1,2-diacylglycerol compound is represented by Chemical Formula 2 in the patent specification.

1,2-diacylglycerol compound, preparation method therefor, and immunomodulator containing same as active ingredient

The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.

Methods for treating thrombocytopenia

The present disclosure relates to a composition for a worm wheel having excellent durability and wear resistance and a worm wheel manufactured using the same. In one embodiment, the composition for a worm wheel includes a polyamide resin, wherein the polyamide resin includes a polyamide 66 resin having a relative viscosity (RV) of about 2.5 or higher and a polyamide 12 resin having a relative viscosity (RV) of about 1.0 or higher.

Composition for worm wheel having excellent durability with wear resistance and worm wheel prepared using the same

Methods for treating neutropenia

The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis

The present invention provides methods for treating, controlling or mitigating hemolytic uremic syndrome (HUS), comprising administering a monoacetyldiacylglycerol compound to a patient in need thereof, as well as compositions useful therefor.

Method for treating hemolytic uremic syndrome

The present invention provides methods for treating, controlling or mitigating paroxysmal nocturnal hemoglobinuria (PNH), comprising administering a monoacetyldiacylglycerol compound to a patient in need thereof, as well as compositions useful therefor.

Method for treating paroxysmal nocturnal hemoglobinuria

The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.

Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis

The present invention relates to a pharmaceutical composition, functional health food composition, quasi-drug composition, and cosmetic composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing, treating or improving atopic dermatitis. The monoacetyldiacylglycerol compound of the present invention has an excellent effect of suppression of IL-4 and IgE secretion, thereby overcoming side effects of an atopic dermatitis treatment agent currently in use, having no toxicity, and exhibiting an excellent treatment effect, and thus can be useful as a composition for preventing, treating, and ameliorating atopic dermatitis.

Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating atopic dermatitis

The present invention relates to an injenane-type diterpene compound derived fromLiou, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the injenane-type diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.

Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same

The present invention relates to a pharmaceutical composition for the prevention or treatment of atopy comprising the extract of, the fraction thereof, of the compound isolated from the same as an active ingredient. More precisely, the extract of, the fraction thereof, or the compound isolated from the same, genekwadapnin or yuanhuacine, of the present invention can increase the secretion of cytokine in Th1 immune cells and suppress atopy in the atopy mouse model, so that the extract of, the fraction thereof, or the compound isolated from the same of the present invention can be effectively used for the prevention or treatment of atopy.

Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis

Growing community of inventors

Seoul, South Korea

Jae Wha Kim